Copied to clipboard!

RAIDs cervical cancer project

The RAIDS project, launched by the Curie Institute in 2013, aims to molecularly characterize cervical cancer (CC) and improve patient risk stratification. As part of the Bio-RAIDS study (NCT02428842), next-generation sequencing was performed on tumor samples (whole-exome sequencing, shallow whole-genome sequencing and RNA-sequencing) identified frequent alterations, including PIK3CA (30%) and prognostic biomarkers like TERT, linked to poor progression-free survival. Over 50 clinically targetable mutations were found, offering new therapeutic opportunities. Transcriptomic analysis also linked specific genes and pathways to prognosis and tumor necrosis.

Type: Cancer Genomics
Archive: European Genome-phenome Archive (EGA)

3 Datasets

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000001479	Here, we describe molecular alterations in 270 cervical cancer patients using 270 tumor frozen samples using RNA-sequencing technology. Tumor samples were obtained from cervical tumor tissue collected at diagnosis. FASTQ files are deposited in the dataset.	Illumina NovaSeq 6000	270
EGAD50000001480	Here, we describe molecular alterations in 291 cervical cancer patients using 291 paired tumor and constitutional frozen samples sequenced using Whole Exome Sequencing technology. Tumor samples were obtained from cervical tumor tissue collected at diagnosis. FASTQ files are deposited files are deposited in the dataset	Illumina NovaSeq 6000	582
EGAD50000001481	shallow Whole Genome sequencing of 302 patients with cervival cancer. Tissue cervical cancer at diagnosis....	Illumina NovaSeq 6000	302